Zentalis Pharmaceuticals, Inc.
ZNTL
$1.79
-$0.025-1.38%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 40.56M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 40.56M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 40.56M | -- | -- |
| SG&A Expenses | 14.61M | 16.76M | 15.74M | 16.37M | 15.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.43M | 65.15M | 65.33M | 67.92M | 62.72M |
| Operating Income | -51.43M | -65.15M | -24.77M | -67.92M | -62.72M |
| Income Before Tax | -40.19M | -88.01M | 10.18M | -61.07M | -55.51M |
| Income Tax Expenses | -27.00K | 266.00K | 143.00K | -135.00K | 31.00K |
| Earnings from Continuing Operations | -40.16M | -88.28M | 10.04M | -60.94M | -55.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 28.00K | 22.00K | 12.00K |
| Net Income | -40.16M | -88.28M | 10.07M | -60.92M | -55.53M |
| EBIT | -51.43M | -65.15M | -24.77M | -67.92M | -62.72M |
| EBITDA | -51.11M | -64.82M | -24.44M | -67.59M | -62.37M |
| EPS Basic | -0.56 | -1.24 | 0.14 | -0.86 | -0.79 |
| Normalized Basic EPS | -0.35 | -0.57 | 0.09 | -0.65 | -0.49 |
| EPS Diluted | -0.56 | -1.24 | 0.14 | -0.86 | -0.79 |
| Normalized Diluted EPS | -0.35 | -0.57 | 0.09 | -0.65 | -0.49 |
| Average Basic Shares Outstanding | 71.11M | 71.04M | 70.90M | 70.83M | 70.61M |
| Average Diluted Shares Outstanding | 71.11M | 71.04M | 71.19M | 70.83M | 70.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
